Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Best Dose of Antivirals in Patients With Both TB and HIV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* ARV naïve subjects~* Documented HIV infection~* Documented TB infection~* Platelet count 40,000/mm3~* Hemoglobin ≥8.0 g/dL~* Absolute neutrophil count (ANC) \>500/mm3~* AST (SGOT), ALT (SGPT), and alkaline phosphatase \<3 X ULN~* Total bilirubin \<2.5 x ULN~* Calculated creatinine clearance ≥60 mL/min~* For women of reproductive potential, negative urine pregnancy test~Exclusion Criteria:~* Unable to provide informed consent.~* History drug abuse that the investigators suspect will interfere with compliance to study medications and visits.~* Patients on hemodialysis.~* Tuberculosis meningitis.~* Women with CD4 \> 250 and men with CD4 \> 400 due to higher risk of hepatotoxicity related to use of NVP.~* Positive serology for hepatitis C.~* Evidence for active hepatitis B including positive serologies for HBsAg, HBeAg, or HBV-DNA. Note: If anti-HBs is positive, patient is eligible for study if liver enzymes are within the parameters indicated in the inclusion criteria~* Women who are breast-feeding~* Known allergy/sensitivity to study drug(s) or their formulations~* Patients with other OIs or intercurrent illness that could affect their ability to take study drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Standard dose nevirapine (200 mg 2x daily) in combination with 2 nucleoside analogs
- 2 (Type: EXPERIMENTAL): High dose nevirapine (400 mg in the morning, 200 mg in the evening) in combination with 2 nucleoside analogs
- 3 (Type: ACTIVE_COMPARATOR): Standard dose efavirenz (600 mg at bedtime) in combination with 2 nucleoside analogs
- 4 (Type: EXPERIMENTAL): High dose efavirenz (800 mg at bedtime) in combination with 2 nucleoside analogs

Based on this trial design, predict the completion outcome and termination type (if applicable).